Literature DB >> 19207969

The global burden of hepatitis C.

Daniel Lavanchy1.   

Abstract

Hepatitis C is of concern both to industrialized and developing countries. Preliminary unpublished estimates of the global burden of disease (GBD) attributable to HCV-related chronic liver disease seem to be substantial. Therefore, the reduction of global mortality and morbidity related to chronic hepatitis C should be a concern to public health authorities, and primary, secondary and tertiary prevention activities should be implemented and monitored in each country, with precise targets set to be reached. In order to decide on national health policies, there is a need to estimate the burden of disease, globally, regionally and nationally. To evaluate the GBD, three components have to be assessed: 1) The global, regional and national burden of morbidity and mortality associated with HCV infection, based on prevalence, incidence, transmission and economics; 2) The natural history of HCV infection, including 'healthy individuals'; and 3) The areas for which more research is needed. A working group was created to assist the World Health organization (WHO) in estimating the GBD associated with HCV infection.

Entities:  

Mesh:

Year:  2009        PMID: 19207969     DOI: 10.1111/j.1478-3231.2008.01934.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  475 in total

1.  Amphipathic alpha-helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B.

Authors:  Jérôme Gouttenoire; Philippe Roingeard; François Penin; Darius Moradpour
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335.

Authors:  Christopher T Lemke; Nathalie Goudreau; Songping Zhao; Oliver Hucke; Diane Thibeault; Montse Llinàs-Brunet; Peter W White
Journal:  J Biol Chem       Date:  2011-01-26       Impact factor: 5.157

3.  Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Authors:  Alexander J Thompson; Rosanna Santoro; Valeria Piazzolla; Paul J Clark; Susanna Naggie; Hans L Tillmann; Keyur Patel; Andrew J Muir; Kevin V Shianna; Leonardo Mottola; Daniela Petruzzellis; Mario Romano; Fernando Sogari; Domenico Facciorusso; David B Goldstein; John G McHutchison; Alessandra Mangia
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

Review 4.  Treatment of non-genotype 1 hepatitis C virus patients.

Authors:  Alessandra Mangia; Leonardo Mottola
Journal:  Curr Gastroenterol Rep       Date:  2012-02

5.  Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.

Authors:  Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

6.  Hepatitis C Virus Therapy-related Skin Manifestations.

Authors:  Brett E Fortune; Shayla Francis; Lisa M Forman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-05

7.  Prisons as social determinants of hepatitis C virus and tuberculosis infections.

Authors:  Niyi Awofeso
Journal:  Public Health Rep       Date:  2010 Jul-Aug       Impact factor: 2.792

8.  Hepatitis C virus E2 envelope glycoprotein core structure.

Authors:  Leopold Kong; Erick Giang; Travis Nieusma; Rameshwar U Kadam; Kristin E Cogburn; Yuanzi Hua; Xiaoping Dai; Robyn L Stanfield; Dennis R Burton; Andrew B Ward; Ian A Wilson; Mansun Law
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

Review 9.  Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

Authors:  Lynn B Dustin; Edgar D Charles
Journal:  Antivir Ther       Date:  2012-12-07

Review 10.  Transfusion transmission of HCV, a long but successful road map to safety.

Authors:  Suganya Selvarajah; Michael P Busch
Journal:  Antivir Ther       Date:  2012-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.